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ABSTRACT
Individual RNA aptamers are often used to modulate
the function of their target proteins, and multi-valent
aptamers have been constructed to enhance their
activity. To expand the utility of aptamers in manip-
ulating and controlling biological processes, here
we advance a general method for the design and
construction of composite aptamers. The resulting
molecular constructs resemble proteins in that they
can form specific interactions with three or more
different partners and be readily integrated into
existing protein regulatory networks. As the first
embodiment of this method, we created a tetra-
valent aptamer that simultaneously binds to two
molecules of the Drosophila protein B52 and two
copies of streptavidin, thus mimicking the function
of an antibody in immunochemical assays.
We demonstrated that the performance of this
‘aptabody’ rivals that of a monoclonal antibody
against B52 in these assays. While this study was
performed in vitro and the composite aptamer we
made was intended to mimic an existing protein,
the same method can be used to accommodate
arbitrary combinations of individual aptamers in
composite molecular contexts, and these con-
structs can be delivered into living cells, where
they are able to utilize existing cellular infrastructure
for their production and processing.
INTRODUCTION
Proteins are able to play a predominant role in most bio-
logical processes largely because an individual protein
molecule can bear multiple speciﬁc sites recognized by
other molecules, including other proteins, which enables
them to assemble into networks or complexes. Novel
protein-like reagents that can be readily integrated into
existing protein networks or complexes of living cells
and organisms are highly desirable in order to understand
and control biological processes (1). However, the gener-
ation and application of novel proteins is diﬃcult, and
alien proteins are usually highly antigenic to an organism.
Structured, low-antigenic RNA molecules recapitulating
the key features of proteins can be created if we possess
two experimental capabilities: (i) the ability to generate
ligands to individual target molecules, and (ii) the ability
to connect and recombine multiple single-site ligands into
a composite molecular entity. The ﬁrst capability has been
realized through the applied in vitro evolution process
(SELEX) that generates RNA aptamers (2,3). To attain
the second capability, here we explore the possibility of
stitching RNA aptamers together with other RNA struc-
tural or functional units to form molecules with multiple
functional sites, which resemble proteins. This allows
aptamer-based molecular constructs to function not only
as inhibitors by blocking binding sites on proteins, but
also as novel connectors.
The recent development of structural nucleic acid nano-
technology provides many examples of composite DNA
and RNA molecules, as well as the general principles for
their design and construction (4,5). This approach utilizes
well-structured components, combined through aﬃnity
and structure to achieve structural predictability with a
precision (or resolution) of 1nm or less in the products.
However, only a few portable elements and aptamers are
structurally well characterized, which makes it diﬃcult to
engineer diverse yet speciﬁc interactions. On the other
hand, although multivalent aptamers, especially dimeric
constructs, have been successfully generated by connecting
aptamers either covalently or noncovalently (6–8), includ-
ing three or more aptamers in a single molecular entity still
poses signiﬁcant technical diﬃculties. In most cases, when
more than one functional unit was to be incorporated into
one RNA molecule, each unit was encoded by a single
segment and these segments were strung together consecu-
tively. A notable and widely used example is the ‘hybrid
RNA’ in the yeast three-hybrid system (9). While this and
other early studies clearly demonstrated that multivalent
RNAs could be designed such that at least two (sometimes
three) domains are simultaneously functional, simple
concatenation often results in misfolding of individual
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stranded stems can be used as points of integration to
assemble multiple RNA components. This strategy has
been used successfully to generate combined ribozyme-
aptamer molecules to implement Boolean logic operations
(10,11).
Our method advanced here is a general and con-
venient scheme of rational modular design using
well-characterized structural elements to connect various
aptamers with conﬁrmed secondary structures. In contrast
to linear concatenation, we utilize two-dimensional graphs
to aid our design. While the three-dimensional structure
of the resulting construct may not be precisely predictable,
it is relatively easy to make sure that each individual
aptamer in the composite is correctly folded and func-
tional. To prove this principle, we constructed a composite
RNA aptamer molecule that mimics a particular protein
in in vitro assays. For an experimentally tractable and
objectively comparable deﬁnition of function for a generic
protein, we took a ‘behavioral’ approach, i.e. determining
whether the non-protein molecule is capable of imitating a
given protein’s ‘behavior’ under conditions deﬁned by the
protein. A non-protein can be considered a mimic of the
protein if the non-protein is able to interact with all part-
ners of the protein with comparable aﬃnity and speciﬁc-
ity, and does not interact with any non-partner of the
protein. Based on this deﬁnition, we made composite apta-
mers that mimic antibodies in immunochemical assays.
Previously, a DNA ‘aptabody’ had been reported, which
is a homodimer of two thrombin-binding aptamers
formed through noncovalent linkage (12). Conceptually
diﬀerent from this DNA molecule, our ‘aptabody’ con-
structs function as connectors between a speciﬁc antigen
and a generic straptavidin-conjugated secondary reagent.
In the present case, the antigen to be detected is the
Drosophila splicing factor B52. We used multiple assays
to demonstrate that the RNA aptabodies were able to
mimic the function of B52 antibodies and their perfor-
mance was quantitatively comparable to a monoclonal
antibody against B52.
MATERIALS AND METHODS
Proteins and antibodies
Full-length B52 protein was expressed in Sf9 cells from
a baculovirius expression system and puriﬁed by the
standard SR protein puriﬁcation procedure (13,14). To
make a His-tagged B52-RNA recognition motifs
(RRMs) construct, a BamHI fragment coding for the
SR domain was deleted from the B52 cDNA and the
remaining cDNA coding for the two RRMs was inserted
into the vector pET-16b (Novagen) to form the plasmid
pET-RRMs(B52). The protein was produced in
BL21(DE3)plysS host cells. Cleared Escherichia coli
lysate was prepared under denaturing condition (8M
Urea), and the protein was refolded on the Ni-NTA
Superﬂow resin (Qiagen) with a step-wise urea gradient (4,
2, 1 and 0M) before elution. Puriﬁed streptavidin and its
conjugates (ImmunoPure streptavidin, horseradish perox-
idase-conjugated streptavidin and Texas Red-conjugated
streptavidin) were purchased from Thermo Scientiﬁc-
Perce Protein Research Products. The monoclonal anti-
body against B52, Bv32, was described previously (15).
The monoclonal penta-His antibody was purchased from
Qiagen.
Aptamer and aptabody constructs
Each DNA template for the homodimers and the mono-
mer derivatives of the streptavidin aptamer S1was made
through bidirectional extension of an overlapping pair of
oligonucleotide primers purchased from Integrated DNA
Technologies. The sequences of these primer pairs (for-
ward and reverse) are listed below. Apt(BBS)2: forward-
76mer (50-GTAATACGACTCACTATAGGGATCGCC
GCGGCTGGTCAACCAGGCGACCGCCGCGGCCA
CAGCGGTGGGCTGGTCA-30); reverse-78mer (50-GA
ATCCCGAAGGATCCGGGAACGCTGGTGGGCGG
TCGCCTGGTTGACCAGCCCACCGCTGTGGCCGC
GGCGGTCGCCT-30). S1: forward-60mer (50-GTAATA
CGACTCACTATAGGGAGTCGACCGACCAGAATC
ATGCAAGTGCGTAAGATAGTC-30); reverse-60mer
(50-ATGAGTCTAGATGTAGACGCACATAATACGC
CCCCGGCCCGCGACTATCTTACGCACTTG-30). S1-
45: forward-45mer (50-GTAATACGACTCACTATAGG
GACCGACCAGAATCATGCAAGTGCG-30); reverse-
45mer (50-CCCGGCCCGCGACTATCTTACGCACTT
GCATGATTCTGGTCGGTC-30). S1-77: forward-58mer
(50-GTAATACGACTCACTATAGGGCCATCGATGC
GGCCGCCGACCAGAATCATGCAAGTGC-30); re-
verse-58mer (50-GGCCATCGATGCGGCCGCCGACC
CGCGACTATCTTACGCACTTGCATGATTCTGGT
CG-30). Apt(S1)2: forward-80mer (50-GTAATACGACTC
ACTATAGGATCCGTGACCGACCAGAATCATGCA
AGTGCGTAAGATAGTCGCGGGTCGGGTCATAC
TCC-30); reverse-80mer (50-GAATCCGCCTCCCGGCC
CGCGACTATCTTACGCACTTGCATGATTCTGGC
CGGGAGTATGACCCGACCCGCGACTATCTT-30).
R-06 dimer: forward-62mer (50-GTAATACGACTCACT
ATAGGATCCGTGACGTCAACACGGTCCCGGAC
GTGTTGACGTCCATA-30); reverse-80mer (50-GAATC
CGCCTCCTCAACACGTCCGGGACCGTGTTGAG
GAGTATGGACGTCAACACGTCCGGGACCGTGT
TGACGTCACGG-30). TAR dimer: forward-65mer (50-G
TAATACGACTCACTATAGGGATCGCCGCCGAG
CCCGGGAGCTCGGCGGCCACAGCGGTGGGAG
C-30); reverse-60mer (50-GAATCCCGAAGGATCCGG
GAACGCTGGTGGGAGCTCCCGGGCTCCCACCG
CTGTGGCCGC-30).
To form the template for the Aptabody Sa-B52, the
templates of Apt(BBS)2 and Apt(S1)2 were digested with
BamHI and the longer pieces were ligated. The ligation
product with correct composition was ampliﬁed using the
following two primers: T7forward (50-GTAATACGACT
CACTATAGG-30) and S1reverse (50-GAATCCGCCTCC
CGGCCCGC-30). The same method was used to generate
the templates for Aptabodies R06-B52 and Sa-TAR: the
longer pieces in each set of the BamHI digestion products
were ligated pair-wisely, Apt(BBS)2 with the R-06 dimer
and the TAR dimer with Apt(S1)2.
e71 Nucleic Acids Research,2009, Vol. 37,No. 9 PAGE2 OF 9All RNA constructs were produced by in vitro tran-
scription from double-stranded DNA templates using
the MEGAshortscript T7 kit (Ambion). After transcrip-
tion, they were extracted with phenol and precipitated
with ethanol. Before use in binding assays or immuno-
chemical assays, they were reconstituted in binding
buﬀer for the assay, heated to 708C for 10min and chilled
on ice.
Binding assays
32P-labeled RNA probes were prepared using the
MAXIscript T7 in vitro transcription kit (Ambion) and
[a-
32P]CTP (GE Healthcare). All binding assays were per-
formed in 20-ml volumes in 1  binding buﬀer. A typical
binding-assay mixture with labeled RNA contained about
20fmol of
32P-labeled RNA probe and diﬀerent amounts
(usually 1–10pmol) of protein. For B52, the binding
buﬀer contained 50mM Tris–Cl (pH 7.6), 200mM potas-
sium acetate, 5mM MgCl2 and 2.5mM dithiothreitol
(DTT) (14). For streptavidin, the binding buﬀer contained
50mM HEPES (pH 7.4), 10mM MgCl2 and 100mM
NaCl (16). Electrophoretic mobility shift assay (EMSA)
was performed at 48C. The B52 binding mix was run on
a 2.2% agarose gel in ¼ TBE buﬀer (22.25mM Tris
base, 22.25mM borate, 0.5mM EDTA); the streptavidin
binding mix was run on a 6% or 7% polyacrylamide gel
in TGB buﬀer (25mM Tris base, 200mM glycine). For
the binding of the aptabody to both B52 and streptavidin,
the binding buﬀer described above for B52 was used (the
S1 aptamer binds streptavidin in this buﬀer as well as in its
original buﬀer).
Dot-blot analysis with aptabody
Serial dilution of B52 was prepared in 1  Binding Buﬀer
[50mM Tris (pH 7.6), 50mM NaCl, 50mM KCL, 15mM
MgCl2] with 1mM phenylmethanesulfonylﬂuoride
(PMSF), and 2mM DTT. Two microliters of each protein
sample was spotted directly onto a piece of 50 6mm
nitrocellulose ﬁlter (Schleicher and Schuell). The ﬁlter
was incubated for 30min at room temperature in a plastic
bag with 1ml Blocking Buﬀer [50mM Tris (pH 7.6),
75mM NaCl, 75mM KCl, 15mM MgCl2, 100mg/ml
yeast total RNA, 2  Denhardt’s solution]. Before
adding the aptabody the ﬁlter was washed twice in
Washing Buﬀer [50mM Tris (pH 7.6), 75mM NaCl,
75mM KCl, 15mM MgCl2]. The aptabody was prepared
in the Binding Buﬀer, heated to 708C for 10min and put
on ice for 5min. Additional components were added so
that the ﬁnal preparation also contains 1mM PMSF,
2mM DTT, 100mg/ml yeast total RNA and 100u/ml
SUPERase In (Ambion). This aptabody preparation at
the concentration of 10mg/ml was incubated with the
ﬁlter for 1h at room temperature, then the ﬁlter was
washed four times with the Washing Buﬀer described
above. Horseradish peroxidase-conjugated streptavidin
was prepared in the Binding Buﬀer with 100mg/ml yeast
total RNA and 100u/ml SUPERase In to reach the ﬁnal
concentration of 1mg/ml, and incubated with the ﬁlter
for one hour at room temperature. Afterwards, the ﬁlter
was washed four times using the Washing Buﬀer with
0.5% Tween-20. To visualize the dots the ﬁlter was incu-
bated with 2ml of ECL plus substrate (GE Healthcare) for
3–5min and exposed to ﬁlm for 1min.
Western blot analyses
Electrophoresis and transfer were performed using Mini-
PROTEAN 3 Electrophoresis Cell and Mini Trans-Blot
Module (Bio-Rad). Western blot with antibodies was per-
formed according to a standard protocol (17). When apta-
bodies were used, this protocol was modiﬁed in the
following aspects. A re-naturing step was added after
transfer: the blot was incubated at room temperature suc-
cessively in 6M, 3M, 1M and 0.1M guanidine-HCl, each
for 30min. The Blocking Buﬀer was the one described
above for dot blot with additional 10% glycerol. Other
solutions were identical to those used for dot-blot analysis.
Staining Drosophila polytene chromosomes with aptabody
Salivary gland polytene chromosomes were prepared from
the Oregon-R strain according to a protocol described
previously (15). The heat shock was performed for
30min at 36.58C. The staining protocol was based on
that of indirect immunoﬂuorescence (15) with the follow-
ing modiﬁcations. PBS was substituted by the Binding
Buﬀer described for dot blot above. The Blocking Buﬀer
was 2  Denhardt’s and 200mg/ml yeast total RNA in
Binding Buﬀer. The primary antibody was substituted
by the aptabody at 200mg/ml, and the secondary antibody
by Texas Red-conjugated streptavidin at 10mg/ml, both
prepared in solution as described above for dot blot.
The Washing Buﬀer was also the one used for dot blot
with 0.5% Tween-20.
RESULTS
A general scheme for molecular design of composite
aptamers
The capability of forming networks requires that protein
molecules be able to bear three or more speciﬁc binding
sites. To recapitulate this feature, we would like to incor-
porate more than three individual aptamers into a single
molecular entity. The major challenge to the design and
construction of such multivalent aptamers is to maintain
the correctly folded structure of each individual aptamer
in the composite molecule. To this end, we have developed
a generic method so that multiple aptamers can be joined
together combinatorially with the help of additional
structural elements. In this method, conﬁrmed secondary
structures serve as a starting point for rational modular
design. As RNA secondary structure formation causes
signiﬁcantly larger free energy change than that involved
in tertiary interactions, the basic properties of the confor-
mational energy landscape of a molecule can be under-
stood at this level (18). As shown in Figure 1A, our
method comprises a set of structural and functional mod-
ules and a protocol to connect them together. The func-
tional modules, in this case individual RNA aptamers,
have known aﬃnities to known targets; the structural
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into a single folded strand.
Aptamers can be regarded as functional modules con-
taining functional ‘loops’ in association with diﬀerent
structural elements. Each ‘loop’ is deﬁned by a single func-
tion without regard to structure. The three types of func-
tional modules are (Figure 1A, ﬁrst row from right to left):
(a) functional apical ‘loops’ and the associated stem
‘neck’; (b) functional internal ‘loops’ embedded in a
stem; and (c) functional internal ‘loops’ constituting the
strand-exchange junction of three or more stems. These
functional modules can be stitched together with the
help of three types of structural modules (Figure 1A,
second row form left to right): (a) multibranch junctions
with known structures, in particular three-way junctions
with known co-axial stacking arrangements of branching
stems, are used to organize and present aptamers; (b)
stems (usually no longer than one helical turn) consisting
of complementary strands that form a double helix, are
used like ‘connective tissues’ to adjust local stability and
relative orientation between aptamers; and (c) stable small
U-turns with known structures, such as hairpins with
stable tetra-loops, are used to maintain the continuity of
the strand, if necessary. A single protocol of stem connec-
tion (Figure 1A, upper right corner) can be applied once
or additional times in the process of design, allowing for
the combinatorial joining of modules together in a single
molecular strand. Once a tentative composite is pieced
together using junctions and U-turns, its secondary struc-
ture can be predicted using free-energy minimization
Figure 1. Rational modular design of composite RNA aptamers. (A) Depiction of the general scheme. Functional ‘loops’ are combined and
organized with the help of structural elements. All elements are connected via double-stranded stems into a putative composite molecule. In the
assembled product of the hypothetical example, thick black lines represent double-stranded stems; solid red dots represent individual aptamers.
(B) Predicted most stable secondary structure of the Aptabody Sa-B52 by mfold (35). This molecule comprises six parts, including four aptamers and
two three-way junctions. Each part is indicated. The thick bar in the middle signiﬁes the sequence corresponding to the BamHI site on the template.
(C) Predicted most stable secondary structure of the Aptabodies R06-B52 (upper left) and Sa-TAR (lower right) by mfold, annotated as in (B).
e71 Nucleic Acids Research,2009, Vol. 37,No. 9 PAGE4 OF 9algorithms (19). If the individual aptamers are predicted to
be misfolded, short double-stranded segments can be
introduced to fortify local structure until each aptamer
is correctly folded in the predicted most stable secondary
structure before being tested in binding assays.
We chose to make an ‘aptabody’ as the ﬁrst embodi-
ment of this scheme because, compared to other proteins,
it is relatively easy to deﬁne the function of antibodies
using standard in vitro immunochemical assays.
Although aptamers are often compared to antibodies,
the analogy between an aptamer and an (monoclonal)
antibody is limited to their speciﬁcity and aﬃnity for the
target or antigen—an individual aptamer is analogous to a
single Fab fragment (20). The aptamer moiety of the DNA
‘aptabody’ for thrombin is only analogous to an F(ab0)2
fragment rather than a full antibody (12). As depicted in
Figure 1B, our ﬁrst RNA aptabody, named Sa-B52, is
designed for the detection of the Drosophila B52 protein
(15). It is a tetra-valent aptamer in which four aptamers
were connected by two three-way junctions: a dimer of a
B52 aptamer (14) forms an F(ab0)2 analog, and a dimer
of a aptamer for streptavidin (16) forms the ‘Fc-like’
part that would be recognizable by any straptavidin-
conjugated secondary reagent. To further demonstrate
the ‘plug-and-play’ feature of the method, we also
designed two more constructs (Figure 1C). One of them,
named ‘R06-B52’, is a di-dimer of the B52 aptamer and an
aptamer for the HIV TAR element, R-06 (21,22);
the other, named ‘Sa-TAR’, contains two copies of
the TAR element and two copies of the streptavidin apta-
mer. This pair could function like the Aptabody Sa-B52
when they form a complex through the TAR R-06
interaction.
Construction of an ‘aptabody’
We have previously identiﬁed a class of B52 aptamers and
through extensive mutational analysis deﬁned a minimized
version as a simple stem–loop (14). These aptamers,
named BBSs (B52 Binding Sequences), bind to the two
RRMs of B52. Our ﬁrst experiment attempted to make
a divalent aptamer and to rigorously demonstrate that
each individual aptamer in the dimeric construct is func-
tional and functions independently. We grafted two copies
of the minimized B52 aptamer to two stems of the three-
way junction of Haloarcula marismortui 5S RNA (23) to
form a new construct, Apt(BBS)2. As shown in Figure 2A,
we used EMSA to examine the activity of the dimer and
found that the aptamer dimer was able to bind two
B52-RRMs molecules to produce two shifted bands.
When the target was present at low concentration, only
one binding site of the dimer was occupied (Figure 2A,
lane 7). As the target concentration increases, both bind-
ing sites were occupied (Figure 2A, lanes 8–10). In theory,
when any macromolecule has two identical binding sites
for a ligand, the two sites would appear to have aﬃnities
diﬀerent by a factor of four, with the ﬁrst site appearing
twice as tight as a monomer and the second appearing half
as tight, if there is no steric hindrance. Indeed, for our
dimeric construct the ﬁrst binding event showed an
apparent aﬃnity higher than the original monomer
(Figure 2A, compare lane 3 with lane 8).
For streptavidin, several aptamers had been published
(16). We picked one of these aptamers, designated ‘S1’ in
B52 0    5     10    20   40    0      5 10    20    40 nM  
**
*
**
* * * *
*
1      2     3       4       5         6        7       8       9     10
AptBBS(#8) Apt(BBS)2
SA 0    5   50    0   5    50    0   5    50    0    5   50 nM
S1 S1-45 S1-77 Apt(S1)2
1      2     3       4      5       6      7       8      9     10     11    12
B52 0
SA  0
A
B
C
7 7 - 1 S 5 4 - 1 S
Figure 2. Binding activity of each individual aptamer in a composite
molecule. (A) Generating a F(ab0)2-like dimeric aptamer for B52. BBS
was the original B52 aptamer [B52 Binding Sequence (14)]. Binding
reactions were run on a 2.2% agarose gel. Shifted bands representing
single and double occupancy of the aptamer binding sites are indicated
by one or two asterisks respectively. (B) Minimization and augmen-
tation of the streptavidin aptamer. S1 was the original full-length strep-
tavidin aptamer (16). In the upper panel all four versions of the
aptamer were run on the same polyacrylamide gel (6%, 37.5:1) to
obtain better comparison of shifted bands. In the lower panel the
same reaction for S1-45 and S1-77 were run on a diﬀerent gel (7%,
19:1) to obtain better resolution of both shifted and un-shifted bands.
The secondary structures of the reduced S1-45 and the augmented
S1-77 are sketched on either side of the lower panel. ‘SA’ stands for
streptavidin. (C) Conﬁrming the activity of individual aptamers in the
di-dimer aptabody. The binding reaction contains increasing concentra-
tion of B52, streptavidin, or both, as indicated, ranging from 5 to
50nM. The gel was 2.2% agarose.
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deﬁne a minimized version that can be incorporated into
our construct. Based on the predicted secondary structure
of S1, we ﬁrst deleted 7nt from the 50 end and 32nt from
the 30 end, reducing the 84-mer aptamer to a 45-mer
named ‘S1-45’. As shown in Figure 2B, this construct
was active, but its aﬃnity to streptavidin seemed to be
lower than the original version. The minimized version
consists of a stem–loop structure with an apical loop
and a side loop. We suspected that it might not be as
stably folded as the original. To test this hypothesis,
we extended the double-stranded stem at the distal end
from the apical loop and corrected an A-C mismatch in
the original sequence to form the construct S1-77
(Figure 2B, compare the two sketches of secondary struc-
ture). This manipulation not only fully restored the aﬃnity
to the original level, but also reduced the formation
of alternative structures (as shown by the reduction of
protein-indiﬀerent bands generated by S1 and S1-45 in
Figure 2B). Next, we designed a dimeric construct
Apt(S1)2 according to the same principle used to make
Apt(BBS)2. Here the three-way junction, System F, was
one previously observed to be extraordinarily stable
among 12 similar variants (24). As shown in Figure 2B
(lanes 11 and 12), both minimized S1 aptamers were fully
functional in this new sequence and structural context;
and the apparent aﬃnity of the dimer for ﬁrst streptavidin
is higher than the monomer (Figure 2B, compare lanes
2 and 11) due to increased local concentration of
binding sites.
When we designed the sequences for the templates that
produced the two dimeric constructs described above, we
included one BamHI site near the 30 end of the Apt(BBS)2
template and another one near the 50 end of the Apt(S1)2
coding sequence. By digesting these two templates with
BamHI and ligating the two longer fragments, we were
able to form the template for the Aptabody Sa-B52
depicted in Figure 1. To conﬁrm that each one of the
four aptamers in this composite was functional, we per-
formed EMSA for the tetra-valent molecule produced by
in vitro transcription to bind B52 and streptavidin either
separately or simultaneously. As shown in Figure 2C, the
aptabody was able to bind both B52 and streptavidin
simultaneously. In addition, this binding assay was also
used to measure the relative avidity of these two types
of aptamers in the composite. Because in an immuno-
chemical assay the binding of the ‘antigen’ B52
occurs before the binding of streptavidin, the ‘F(ab0)2’
end of the molecule should have higher avidity to B52
than the ‘Fc’ end to streptavidin, thus ensuring the
stable formation of B52–aptabody–streptavidin triple
complex. We chose the two aptamers, BBS and S1,
according to their reported Kd, which were 20nM and
70nM, respectively (14,16). As shown in Figure 2C, this
diﬀerence in their Kd was apparently maintained in the
context of the aptabody, as revealed by the relative avidity
of the aptabody for B52 and streptavidin (note that
at 50nM B52 binding was saturating but streptavidin
binding was not, presumably due to insuﬃcient amount
of streptavidin present).
Aptabodies as functional mimics of antibodies in
immunochemical assays
There are three broad types of immunochemical assays, in
which antigens are presented in diﬀerent environments.
First, in assays like western blot analysis, the antigens
are extracted from cells or tissues and immobilized on
the surface of solid matrices. Second, to reveal the local-
ization and quantity of antigens, they are ﬁxed in their
native but complex cellular context for in situ immuno-
staining. Third, antigens in solution may be detected by
antibody and precipitated out of the aqueous phase. In all
three types of assays, the antigen–antibody complex is
further recognized by a secondary reagent (usually a sec-
ondary antibody) that binds the antibody and bears an
additional label or signal for detection or separation.
The diversity of antigen display described above often
requires diﬀerent properties of antibodies. A single anti-
body or its aptabody mimic may not be able to perform
equally well in diﬀerent assays. As aptamers were selected
in solution, most commonly in buﬀers that resemble the
physiological condition of the target molecule, it is not
guaranteed that they will be functional in other diﬀerent
environments. As our binding assays described in the pre-
vious section have already demonstrated the functionality
of each individual aptamer (Figure 2A and B) and the
simultaneous binding of B52 and streptavidin by the apta-
body in solution (Figure 2C), here we focused our tests
of the aptabody in several assay formats deﬁned by anti-
bodies, in which B52 is presented in immobilized or ﬁxed
forms.
We started our test by asking whether the B52 aptamer
in the context of an aptabody were able to recognize B52
on the surface of a membrane, and whether the streptavi-
din aptamer in this molecule could simultaneously bind
horseradish peroxidase (HRP)-conjugated streptavidin.
For this purpose, we set up a dot-blot analysis to visualize
puriﬁed B52 protein spotted directly on nitrocellulose
membrane. After testing several diﬀerent types of blocking
buﬀers and several diﬀerent concentrations of aptabody,
streptavidin and HRP substrate, we established a protocol
that is described in detail in the ‘Materials and Methods’
section. As shown in Figure 3A, using this protocol,
<5min of exposure was required to clearly visualize 0.5
ng of B52, and these ‘dots’ would not appear if either B52
or the aptabody was omitted from the protocol (data not
shown). In this assay the concentration of aptabody
(10mg/ml, 150nM) is comparable to the concentration of
antibody in a typical western blot assay [1–50mg/ml (17);
the molecular weight of an antibody is roughly twice that
of the aptabody]. The HRP-conjugated streptavidin was
also used in a concentration similar to that of HRP-
conjugated secondary antibody for western blots [1mg/
ml, 10nM in our protocol compared to 5–0.5mg/ml
(17)]. The sensitivity of this assay was approaching the
detection limit of antibodies, which is  2fmol [(17),
0.1ng for a 50-kDa protein].
Compared with the dot blot assay described above, the
western blot analysis commonly used in molecular biology
is diﬀerent in two aspects. First, unlike direct spotting,
proteins are usually separated on a polyacrylamide gel
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the membrane. Second, while an aptabody is analogous to
a monoclonal antibody, in most cases the antibody used
for western blot is polyclonal. Therefore, to determine
whether an aptabody can faithfully and eﬃciently mimic
the function of an antibody in such an assay, a fair but
strict comparison of the performance should be conducted
between an aptabody and a monoclonal antibody under
the condition deﬁned by the latter. For a western blot
with the aptabody, we mixed two diﬀerent forms of B52
with an unrelated protein, the heat-shock factor (HSF).
The B52 protein is composed of two RRMs and an ‘SR
domain’ rich in serine and arginine (15). The aptamer
binds the two RRMs but not the SR domain (14). The
un-tagged full-length B52 used in this assay was puriﬁed
from Sf9 cells; the RRMs construct was puriﬁed from
E. coli with a His-tag. The HSF protein also bears a
His-tag. Therefore, this trio could be used to compare
the aptabody to a monoclonal antibody against B52 (15)
as well as a commercially available anti-His antibody.
(In a more realistic demonstration of speciﬁcity, cell
extract or similar samples would have been used, but
our un-modiﬁed RNA constructs were not designed to
withstand RNases that may exist in such samples.)
We compared the performance of antibodies and
the Aptabody Sa-B52 in detecting protein samples in the
1–10-ng range. As shown in Figure 3B, both monoclonal
antibodies detected their respective antigen and produced
signals with comparable intensity. The aptabody detected
both forms of B52. Compared to the monoclonal antibody
against B52, its signal for the full-length protein was even
stronger. While its signal for the RRMs-only construct
was weaker, it was stronger than that produced by the
anti-His antibody. To further conﬁrm the mechanism of
aptabody function, we included in this assay an additional
pair of aptabodies—the two constructs depicted in
Figure 1C, Aptabodies R06-B52 and Sa-TAR. As shown
in the ﬁgure, one more lap in the relay from the ‘antigen’
to the signal did not make it fail to detect the ‘antigen’,
although the signal is signiﬁcantly weakened. As in the
dot-blot assay, the concentration of aptabodies used
here is similar if not identical to the concentration of
antibodies.
The B52 protein was originally identiﬁed by its unique
pattern visualized on the polytene chromosomes of
Drosophila salivary glands using its monoclonal antibody
in immunoﬂuorescent microscopy (15). After obtaining
positive results with the B52 aptabody in western blot
analysis, we further tested whether we would be able to
detect B52 in situ on these polytene chromosomes. Here
we adopted the indirect immunoﬂurescence protocol by
replacing the primary and secondary antibodies with sim-
ilar amount and concentration of Aptabody Sa-B52 and
Texas Red-conjugated streptavidin. The blocking solution
was also duly modiﬁed in which non-fat milk powder in
phosphate buﬀer was replaced by Denhardt’s solution
with nonspeciﬁc RNA. As shown in Figure 3C, this pro-
tocol using aptabody reproduced the banding pattern of
B52 distribution formerly generated by B52 monoclonal
antibody (15). In particular, we used salivary glands under
heat shock to reproduce the characteristic ‘bracketing’
pattern of B52at the de-condensed heat-shock loci on
Chromosome 3R (Figure 3C, upper right corner). When
the aptabody was omitted in the protocol, there was no
ﬂuorescent signal on the polytene chromosome under
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Figure 3. Performance of antibodies in immunochemical assays.
(A) Dot-blot analysis. The histogram quantiﬁes three independent
assays with the intensity normalized to the highest amount of B52
used (=1.0). Error bars reﬂect standard deviations. The image of one
representative membrane is show under the histogram. (B) Western blot
analysis with monoclonal antibodies and aptabodies. The protein
sample loaded to each lane was identical. The smear of full-length
B52 was possibly caused by heterogeneity of the phosphorylation
status in the SR domain. (C) Fluorescence staining of polytene chro-
mosomes. The main panel shows broad distribution of B52 on inter-
bands and puﬀs. The inset at the upper right corner shows a segment of
chromosome 3R after heat treatment, with the cytogenetic loci contain-
ing the major heat-shock genes at 87A/C marked by arrowheads.
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shown). Taken together, these experiments demonstrated
the capability of the aptabody to mimic an antibody in
multiple assay formats of immunochemistry.
DISCUSSION
Inside cells, mechanisms bringing two protein molecules
together play an important role in cellular regulatory net-
works (25,26). The same principle can be employed in
therapeutic or experimental applications (27,28). For this
purpose, we have developed a general method for rational
modular design of composite aptamer molecules with mul-
tiple valencies and speciﬁcities. Individual aptamers have
been used like drugs to block protein function (29), and
either covalently or noncovalently linked homo-polymeric
aptamers have been used to enhance avidity or activate
the target (6–8,12,30,31). The utility of aptamers will be
dramatically expanded if they can be used as building
blocks of molecular interconnectors that create novel con-
nectivity between proteins. As a preliminary study along
this line, here we demonstrated in vitro that two unrelated
proteins from two diﬀerent organisms, the splicing factor
B52 of Drosophila melanogaster and streptavidin from
Streptomyces avidinii, can be bridged by a constructed
RNA molecule derived from aptamers for these proteins.
This multivalent composite aptamer recapitulated features
of antibodies in a single un-modiﬁed RNA molecule, and
functioned in three standard immunochemical assay for-
mats deﬁned by antibodies. Previously, direct biotin con-
jugates of aptames were used to detect their target proteins
(12,20). But our intention was not to develop a type of
reagent that would out-perform the biotinylated aptamers.
We chose this simple and even seemingly contrived exam-
ple in order to allow the underlying idea relevant to RNA
structure and function to stand out more clearly.
While demonstrating the capability of a composite
aptamer to mimic a particular protein under speciﬁed con-
ditions is a necessary proof of principle, the utility of this
type of constructs is not limited to molecular ‘prostheses’.
By splicing together more than one type of RNA aptamer,
our method promises to create combinations of binding
sites that do not correspond to that of any existing pro-
tein. Such ‘protein-like’ molecules can be used to create
new connectivity in protein networks. To appreciate the
utility of this type of molecular interconnectors, it is help-
ful to compare them with two commonly used approaches
to manipulating and controlling biological processes, as
depicted in Figure 4. Here we consider a generic protein
‘A’, whose function as a node in a network is realized
through two discrete sites, ‘i’ and ‘ii’. Genetic methods
may cause the absence or malfunction of the entire protein
(total deletion of the gene or conditional mutants); it
may also abolish an individual connection to a protein
(deletion or point mutation of site ‘ii’ eliminates its inter-
action with ‘C’). Small-molecular-weight compounds
(drugs), in general, function as inhibitors of protein by
blocking active sites. In this case a site ‘i’ mimic inhibits
the function of protein ‘B’. Although a few drugs have
been developed to induce proximity of two speciﬁc
proteins (32), there is no general scheme to use genetics
or small molecules to create new connectivity between
proteins.
In order to form a network, a ‘protein-like’ molecule
should be able to possess at least three speciﬁc binding
sites: single-site molecules can only form dyadic interac-
tions and double-site molecules can only form linear
chains. Moreover, the cellular protein network possesses
a scale-free topology and some ‘hub’ proteins interact with
many partners through multiple sites (33). Therefore, it
is critical for a generic method to provide means to accom-
modate three or more aptamers in a composite without
diﬃculty. To achieve this goal, we used well-characterized
structural elements to organize and present multiple apta-
mers. A critical feature of our method is the use of three-
way junctions. In natural RNAs, three-way junctions
occur frequently and often play essential architectural
roles. Crystal structures are becoming available for more
and more three-way junctions in folded RNAs (23) and
general folding rules have been derived for them (34).
We incorporate this type of additional structural informa-
tion into our design at the level of secondary structure to
compensate for the lack of information regarding aptamer
structure. Our data clearly demonstrated that each of
the four aptamers is active in the composite aptabody.
Genetic Manipulations
Small-molecule Compounds (drugs)
RNA Constructs
A
B
i
ii C
“Conditional”
mutant
Point mutation
of site ii
Deletion
of site ii
Inhibitor of B (mimicking site i)
Blocker
(Inhibitor)
Molecular
prosthesis
Novel
connector
Individual
Aptamers
Composite
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Figure 4. Composite RNA aptamers as functional mimics of protein.
A hypothetical protein ‘A’ is used as a generic example, whose function
is realized by interaction with proteins ‘B’ and ‘C’ through sites ‘i’ and
‘ii’. RNA aptamers are compared with genetic methods and small
molecular compounds for their capability to inhibit, mimic, and
modify the function of protein ‘A’ and its partners.
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by a computer program, with further improvements to
maximize the base paring, minimize the RNA strand
length, and provide alternative arrangements of aptamers
in a combinatorial manner. This type of molecule can
not only be used in vitro as shown here, but also in vivo.
If a ‘protein-like’ composite aptamer is delivered into
organisms as a synthetic gene, its production could be
regulated temporally and spatially using diﬀerent promo-
ters (30). In this way a new RNA molecule could be read-
ily integrated into an existing protein network.
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